Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the ...

PHILADELPHIA, PA (December 28, 2011)Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab ...

(Fox Chase Cancer Center) Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new Phase 3 clinical trial conducted by the Gynecologic Oncology Group showed that a targeted therapy called bevacizumab (Avastin) ...

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation ...

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo.

Alexion Pharmaceuticals, Inc. today announced that the European Commission (EC) has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).

A study published Online First in The Lancet Oncology reveals that patients who suffer from the most common form of lung cancer and whose tumors express high levels of epidermal growth factor receptor (EGFR) tend to benefit more from being treated with cetuximab and have a longer life-expectancy compared with ...

By Steven Reinberg HealthDay Reporter WEDNESDAY, Nov. 2 (HealthDay News) -- A combination of radiation and hormone therapy prolongs survival among men whose cancer has spread beyond the prostate, Canadian and U.K. researchers report. These men have what is called high-risk, or ...

Combining the epidermal growth factor receptor (EGFR) inhibitor cetuximab with conventional chemotherapy improves survival in patients who have had complete resection of colorectal liver metastases that were initially judged to be unresectable, according to data presented at the 2011 European Multidisciplinary Cancer Congress (EMCC)...

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated ...

The Department of Veterans Affairs (VA) is extending retroactive traumatic injury benefits to Servicemembers who suffered qualifying injuries during the period Oct. 7, 2001 to Nov. 30, 2005, regardless of the geographic location where the injuries occurred.

Laboratory Corporation of America Holdings today announced that LabCorp is extending until 5:00 p.m., New York City time, on October 7, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc..